Acute Myelogenous Leukemia - Treatment Options, Symptoms, Causes & Diagnosis from MedifocusHealth

Acute Myelogenous Leukemia > What Your Doctor is Reading About Acute Myelogenous Leukemia > Clinical Trials

Clinical Trials

1. Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500).

Author: Petersdorf SH; Rankin C; Head DR; Terebelo HR; Willman CL; Balcerzak SP; Karnad AB; Dakhil SR; Appelbaum FR;
Institution: Division of Medical Oncology, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Puget Sound Oncology Consortium, Seattle, Washington 98109, USA. spetersd@u.washington.edu
Journal: Am J Hematol. 2007 Dec;82(12):1056-62.
Abstract URL: Click here to view abstract

2. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).

Author: Vehreschild JJ; Bohme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA;
Institution: Klinikum der Universitat zu Koln, Klinik I fur Innere Medizin, Studienzentrum Infektiologie II, 50937 Koln, Germany.
Journal: J Infect. 2007 Nov;55(5):445-9. Epub 2007 Sep 6.
Abstract URL: Click here to view abstract

3. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.

Author: Pollyea DA; Artz AS; Stock W; Daugherty C; Godley L; Odenike OM; Rich E; Smith SM; Zimmerman T; Zhang Y; Huo D; Larson R; van Besien K;
Institution: Department of Internal Medicine, University of Chicago Hospitals, Chicago, IL 60637, USA.
Journal: Bone Marrow Transplant. 2007 Dec;40(11):1027-32. Epub 2007 Sep 10.
Abstract URL: Click here to view abstract

4. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences.

Author: Sorror ML; Giralt S; Sandmaier BM; De Lima M; Shahjahan M; Maloney DG; Deeg HJ; Appelbaum FR; Storer B; Storb R;
Institution: Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA 98109-1024, USA. msorror@fhcrc.org
Journal: Blood. 2007 Dec 15;110(13):4606-13. Epub 2007 Sep 14.
Abstract URL: Click here to view abstract

5. Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia.

Author: Fianchi L; Pagano L; Leoni F; Storti S; Voso MT; Valentini CG; Rutella S; Scardocci A; Caira M; Gianfaldoni G; Leone G;
Institution: Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Roma, Italy. luana.fianchi@rm.unicatt.it
Journal: Ann Oncol. 2008 Jan;19(1):128-34. Epub 2007 Sep 28.
Abstract URL: Click here to view abstract

6. Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older.

Author: Eom KS; Kim HJ; Min WS; Lee S; Min CK; Cho BS; Kim SY; Kim YJ; Lee DG; Choi SM; Cho SG; Kim DW; Lee JW; Shin WS; Kim CC;
Institution: Catholic Hematopoietic Stem Cell Transplantation Center, St Mary's Hospital, The Catholic University of Korea, Seoul, Korea. dreom@catholic.ac.kr
Journal: Eur J Haematol. 2007 Nov;79(5):398-404. Epub 2007 Oct 4.
Abstract URL: Click here to view abstract

7. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.

Author: Pieters R; Schrappe M; De Lorenzo P; Hann I; De Rossi G; Felice M; Hovi L; LeBlanc T; Szczepanski T; Ferster A; Janka G; Rubnitz J; Silverman L; Stary J; Campbell M; Li CK; Mann G; Suppiah R; Biondi A; Vora A; Valsecchi MG;
Institution: Dutch Childhood Oncology Group (DCOG, Netherlands) Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands. rob.pieters@erasmusmc.nl
Journal: Lancet. 2007 Jul 21;370(9583):240-50.
Abstract URL: Click here to view abstract

8. A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.

Author: Karp JE; Giles FJ; Gojo I; Morris L; Greer J; Johnson B; Thein M; Sznol M; Low J;
Institution: Leukemia Program, Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231-1000, USA. jkarp2@jhmi.edu
Journal: Leuk Res. 2008 Jan;32(1):71-7. Epub 2007 Jul 20.
Abstract URL: Click here to view abstract

9. Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience.

Author: Gutierrez-Aguirre CH; Cantu-Rodriguez OG; Gonzalez-Llano O; Salazar-Riojas R; Martinez-Gonzalez O; Jaime-Perez JC; Morales-Toquero A; Tarin-Arzaga LC; Ruiz-Arguelles GJ; Gomez-Almaguer D;
Institution: Servicio de Hematologia del Hospital Universitario Dr Jose E. Gonzalez, Universidad Autonoma de Nuevo Leon, Monterrey, NL, Mexico.
Journal: Hematology. 2007 Jun;12(3):193-7.
Abstract URL: Click here to view abstract

10. Autologous bone marrow transplantation for children with AML in first remission.

Author: Neudorf S; Sanders J; Kobrinsky N; Alonzo TA; Buxton A; Buckley JD; Howells W; Gold S; Barnard DR; DeSwarte J; Kalousek D; Lange BJ; Woods WG;
Institution: Children's Hospital of Orange County, 455 S. Main Street, Orange, CA 92868, USA. sneudorf@choc.org
Journal: Bone Marrow Transplant. 2007 Aug;40(4):313-8. Epub 2007 Jun 11.
Abstract URL: Click here to view abstract

11. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.

Author: Attar EC; De Angelo DJ; Supko JG; D'Amato F; Zahrieh D; Sirulnik A; Wadleigh M; Ballen KK; McAfee S; Miller KB; Levine J; Galinsky I; Trehu EG; Schenkein D; Neuberg D; Stone RM; Amrein PC;
Institution: Hematology/Oncology Unit, Massachusetts General Hospital, Boston, MA 02114, USA. eattar@partners.org
Journal: Clin Cancer Res. 2008 Mar 1;14(5):1446-54.
Abstract URL: Click here to view abstract

12. Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG).

Author: Miyawaki S; Kawai Y; Takeshita A; Komatsu N; Usui N; Arai Y; Ishida F; Morii T; Kano Y; Ogura M; Doki N; Ohno R;
Institution: Leukemia Research Center, Saiseikai Maebashi Hospital, Gunma 371-0821, Japan. miyawaki@mail.wind.ne.jp
Journal: Int J Hematol. 2007 Nov;86(4):343-7.
Abstract URL: Click here to view abstract

13. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.

Author: Creutzig U; Buchner T; Sauerland MC; Zimmermann M; Reinhardt D; Dohner H; Schlenk RF;
Institution: Pediatric Hematology/Oncology, Children's Hospital, University of Munster, Munster, Germany. ursula@creutzig.de
Journal: Cancer. 2008 Feb 1;112(3):562-71.
Abstract URL: Click here to view abstract

14. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.

Author: Valcarcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Pinana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simon JA; Sierra J; Valcarcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Pinana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simon JA; Sierra J;
Institution: Hospital de la Santa Creu i Sant Pau, Universitat Autonoma Barcelona, Barcelona, Spain. dvalcarcel@santpau.es
Journal: J Clin Oncol. 2008 Feb 1;26(4):577-84. Epub 2007 Dec 17.
Abstract URL: Click here to view abstract

15. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia.

Author: Frankel A; Liu JS; Rizzieri D; Hogge D; Frankel A; Liu JS; Rizzieri D; Hogge D;
Institution: Scott & White Cancer Research Institute, Temple, TX, USA.
Journal: Leuk Lymphoma. 2008 Mar;49(3):543-53.
Abstract URL: Click here to view abstract

16. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.

Author: Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB; Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB;
Institution: Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. smallt@mskcc.org
Journal: Biol Blood Marrow Transplant. 2007 Feb;13(2):235-44.
Abstract URL: Click here to view abstract

17. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

Author: Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D; Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D;
Institution: University of Cologne, Cologne, Germany. oliver.cornely@uni-koeln.de
Journal: N Engl J Med. 2007 Jan 25;356(4):348-59.
Abstract URL: Click here to view abstract

18. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.

Author: Thomas X; Raffoux E; Botton S; Pautas C; Arnaud P; de Revel T; Reman O; Terre C; Corront B; Gardin C; Le QH; Quesnel B; Cordonnier C; Bourhis JH; Elhamri M; Fenaux P; Preudhomme C; Michallet M; Castaigne S; Dombret H;
Institution: Department of Hematology, Hopital Edouard Herriot, Lyon, France. xavier.thomas@chu-lyon.fr
Journal: Leukemia. 2007 Mar;21(3):453-61. Epub 2007 Jan 25.
Abstract URL: Click here to view abstract

19. Outcomes in childhood AML in the absence of transplantation in first remission--Children's Cancer Group (CCG) studies 2891 and CCG 213.

Author: Castellino SM; Alonzo TA; Buxton A; Gold S; Lange BJ; Woods WG; Castellino SM; Alonzo TA; Buxton A; Gold S; Lange BJ; Woods WG;
Institution: ETSU Quillen College of Medicine, Johnson City, Tennessee, USA. scastell@wfubmc.edu
Journal: Pediatr Blood Cancer. 2008 Jan;50(1):9-16.
Abstract URL: Click here to view abstract

20. Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.

Author: Roboz GJ; Giles FJ; Ritchie EK; Allen-Bard S; Curcio TJ; Wilkes MA; Park SL; Kantarjian HM; Faderl S; Ravandi F; Kelner MJ; Feldman EJ;
Institution: Weill Medical College of Cornell University, The New York Presbyterian Hospital, New York, NY 10021, USA. gar2001@med.cornell.edu
Journal: J Clin Oncol. 2007 Jan 1;25(1):10-5. Epub 2006 Dec 4.
Abstract URL: Click here to view abstract

21. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.

Author: Giles F; Rizzieri D; Karp J; Vey N; Ravandi F; Faderl S; Khan KD; Verhoef G; Wijermans P; Advani A; Roboz G; Kantarjian H; Bilgrami SF; Ferrant A; Daenen SM; Karsten V; Cahill A; Albitar M; Mufti G; O'Brien S;
Institution: The University of Texas M.D. Anderson Cancer Center, Department of Leukemia, Houston, TX 77030, USA. frankgiles@aol.com
Journal: J Clin Oncol. 2007 Jan 1;25(1):25-31. Epub 2006 Dec 4.
Abstract URL: Click here to view abstract

22. Unrelated donor bone marrow transplantation using a chemotherapy-only preparative regimen for adults with high-risk acute myelogenous leukemia.

Author: Ayash LJ; Ratanatharathorn V; Braun T; Silver SM; Reynolds CM; Uberti JP;
Institution: Department of Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USA. ayashl@karmanos.org
Journal: Am J Hematol. 2007 Jan;82(1):6-14.
Abstract URL: Click here to view abstract

23. Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation.

Author: Yang DH; Lee JJ; Mun YC; Shin HJ; Kim YK; Cho SH; Chung IJ; Seong CM; Kim HJ;
Institution: Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, Republic of Korea.
Journal: Am J Hematol. 2007 Jan;82(1):1-5.
Abstract URL: Click here to view abstract

24. Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia.

Author: Lehrnbecher T; Zimmermann M; Reinhardt D; Dworzak M; Stary J; Creutzig U;
Institution: Pediatric Hematology and Oncology, University of Frankfurt, Germany, and Children's Cancer Research Institute, St Anna Kinderspital, Vienna, Austria. thomas.lehrnbecher@kgu.de
Journal: Blood. 2007 Feb 1;109(3):936-43. Epub 2006 Sep 28.
Abstract URL: Click here to view abstract

25. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.

Author: Taksin AL; Legrand O; Raffoux E; de Revel T; Thomas X; Contentin N; Bouabdallah R; Pautas C; Turlure P; Reman O; Gardin C; Varet B; de Botton S; Pousset F; Farhat H; Chevret S; Dombret H; Castaigne S;
Institution: Departement d'Hematologie et Oncologie, Hopital Mignot, Versailles, Universite de Versailles-Saint Quentin en Yvelines, France.
Journal: Leukemia. 2007 Jan;21(1):66-71. Epub 2006 Oct 19.
Abstract URL: Click here to view abstract

26. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.

Author: Lancet JE; Gojo I; Gotlib J; Feldman EJ; Greer J; Liesveld JL; Bruzek LM; Morris L; Park Y; Adjei AA; Kaufmann SH; Garrett-Mayer E; Greenberg PL; Wright JJ; Karp JE;
Institution: H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA. lancetje@moffitt.org
Journal: Blood. 2007 Feb 15;109(4):1387-94. Epub 2006 Nov 2.
Abstract URL: Click here to view abstract

27. HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia.

Author: Herr AL; Labopin M; Blaise D; Milpied N; Potter M; Michallet M; Heit W; Ferrara F; Esteve J; Arcese W; Ehninger G; Rowe JM; Kobbe G; Rosselet A; Bunjes D; Rio B; Brune M; Nagler A; Gorin NC; Frassoni F; Rocha V;
Institution: Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Journal: Leukemia. 2007 Jan;21(1):129-35. Epub 2006 Nov 23.
Abstract URL: Click here to view abstract

28. A multicenter randomized, double-blind, placebo-controlled late-phase II/III study of recombinant human interleukin 11 in acute myelogenous leukemia.

Author: Usuki K; Urabe A; Ikeda Y; Ohashi Y; Mizoguchi H; Takaku F;
Institution: Division of Hematology, NTT Kanto Medical Center, Tokyo, Japan. usuki@kmc.mhc.east.ntt.co.jp
Journal: Int J Hematol. 2007 Jan;85(1):59-69.
Abstract URL: Click here to view abstract

29. Post-remission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy - results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial.

Author: Gardin C; Turlure P; Fagot T; Thomas X; Terre C; Contentin N; Raffoux E; de Botton S; Pautas C; Reman O; Bourhis JH; Fenaux P; Castaigne S; Michallet M; Preudhomme C; de Revel T; Bordessoule D; Dombret H;
Institution: Department of Hematology, Hopital Avicenne, Bobigny, France.
Journal: Blood. 2007 Mar 6;.
Abstract URL: Click here to view abstract

30. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.

Author: Harousseau JL; Lancet JE; Reiffers J; Lowenberg B; Thomas X; Huguet F; Fenaux P; Zhang S; Rackoff W; De Porre P; Stone R;
Institution: Service d'Hematologie, Hotel Dieu, Nantes, France.
Journal: Blood. 2007 Mar 9;.
Abstract URL: Click here to view abstract

31. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.

Author: Oran B; Giralt S; Saliba R; Hosing C; Popat U; Khouri I; Couriel D; Qazilbash M; Anderlini P; Kebriaei P; Ghosh S; Carrasco-Yalan A; de Meis E; Anagnostopoulos A; Donato M; Champlin RE; de Lima M; Oran B; Giralt S; Saliba R; Hosing C; Popat U; Khouri I; Couriel D; Qazilbash M; Anderlini P; Kebriaei P; Ghosh S; Carrasco-Yalan A; de Meis E; Anagnostopoulos A; Donato M; Champlin RE; de Lima M;
Institution: M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Journal: Biol Blood Marrow Transplant. 2007 Apr;13(4):454-62. Epub 2007 Feb 8.
Abstract URL: Click here to view abstract

32. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.

Author: Heidel F; Cortes J; Rucker FG; Aulitzky W; Letvak L; Kindler T; Huber C; Dohner H; Kantarjian H; Fischer T; Heidel F; Cortes J; Rucker FG; Aulitzky W; Letvak L; Kindler T; Huber C; Dohner H; Kantarjian H; Fischer T;
Institution: Department Internal Medicine III, University-Hospital, Mainz, Germany.
Journal: Cancer. 2007 Mar 1;109(5):907-14.
Abstract URL: Click here to view abstract

33. The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes: a Japanese multicenter randomized, controlled study.

Author: Ito Y; Ohyashiki K; Yoshida I; Takeuchi M; Aoyama Y; Mugitani A; Matsuura Y; Wakita H; Matsuda M; Sakamoto E; Kiguchi T; Urabe A; Tamura K; Kanamaru A; Masaoka T; Ito Y; Ohyashiki K; Yoshida I; Takeuchi M; Aoyama Y; Mugitani A; Matsuura Y; Wakita H; Matsuda M; Sakamoto E; Kiguchi T; Urabe A; Tamura K; Kanamaru A; Masaoka T;
Institution: First Department of Internal Medicine (Hematology Division), Tokyo Medical University, Tokyo, Japan. yito@tokyo-med.ac.jp
Journal: Int J Hematol. 2007 Feb;85(2):121-7.
Abstract URL: Click here to view abstract

34. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.

Author: Horton TM; Pati D; Plon SE; Thompson PA; Bomgaars LR; Adamson PC; Ingle AM; Wright J; Brockman AH; Paton M; Blaney SM;
Institution: Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA. tmhorton@txccc.org
Journal: Clin Cancer Res. 2007 Mar 1;13(5):1516-22.
Abstract URL: Click here to view abstract